A new study published in the journal Diabetes, Obesity and Metabolism has found that cannabidiol (CBD) significantly improves metabolic health and reduces inflammation and liver fibrosis in a mouse model of polycystic ovary syndrome (PCOS) with androgenic obesity.
Researchers from Heidelberg University and the University of Córdoba used a well-established PCOS model, inducing androgen excess and feeding mice a high-fat diet to replicate the metabolic complications commonly seen in PCOS, including obesity, insulin resistance, and fatty liver disease. The mice were then treated with either oral or intraperitoneal CBD at doses of 10 or 20 mg/kg per day for four weeks.
The study found that CBD treatment led to notable reductions in weight gain and fat mass, as well as improvements in glucose tolerance and insulin sensitivity. These benefits were consistent regardless of whether the compound was administered orally or by injection.
In addition to the metabolic improvements, CBD treatment reduced markers of inflammation in fat tissue and lowered liver fibrosis. Histological analysis revealed fewer inflammatory immune cells and reduced collagen deposition in the liver, alongside diminished expression of alpha-smooth muscle actin (α-SMA), a marker of fibrotic activity.
Proteomic analysis further showed that CBD reversed liver protein signatures associated with metabolic stress, including the downregulation of pathways tied to glycolysis, oxidative stress, and inflammation. Several liver proteins commonly elevated in human metabolic liver disease were significantly reduced by CBD, and blood levels of inflammatory markers like IL-1β and PLA2G4A also decreased.
“These findings suggest that CBD has the potential to broadly modulate metabolic, inflammatory and fibrotic processes involved in PCOS,” the authors concluded. While the study did not include comparisons with standard treatments like metformin or GLP-1 receptor agonists, the researchers say CBD’s favorable safety profile and multi-targeted effects make it a compelling candidate for further clinical research, especially as an adjunct for patients not responding to existing therapies.
More articles from The Marijuana Herald can be found below.
